Unichem Laboratories Limited (UNICHEMLAB) fundamentals
Unichem Laboratories Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as UNICHEMLAB (ISIN INE351A01035). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Unichem Laboratories Limited does
Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
Valuation and market data
| Last close | ₹473.95 |
|---|---|
| Market capitalisation | ₹3,337 crore |
| Enterprise value | ₹3,182 crore |
| P/E (TTM) | 13.20 |
| Price to book | 1.23 |
| Price to sales (TTM) | 0.84 |
| Book value per share | ₹385.95 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 07 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,265 crore | ₹292 crore | ₹253 crore | 35.91 |
| Mar 2025 | ₹2,146 crore | ₹155 crore | ₹138 crore | 19.53 |
| Mar 2024 | ₹1,817 crore | ₹-85 crore | ₹-94 crore | -13.32 |
| Mar 2023 | ₹1,382 crore | ₹-176 crore | ₹-202 crore | -28.72 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 70.2% |
|---|---|
| Foreign institutions (FII) | 2.7% |
| Mutual funds | 8.7% |
| Other domestic institutions | 0.8% |
| Retail and others | 17.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.